Hepatitis Therapeutics Market Size & Forecast Report, 2014 - 2025

The global hepatitis therapeutics market size is expected to value at USD 25.8 billion by 2025, during the forecast period. The market is subject to witness substantial growth due to the growing incidences related to hepatitis infections, increasing consumption of alcohol in large quantities, and easy accessibility for treatment and medicines for hepatitis disorder. Some of the critical factors responsible for driving the growth of the market over the forecast period, increase in the number of autoimmune disorders and an increase in medical expenditures by regional governments. One of the major concerns regarding the prevalence of hepatitis is increasing the number of deaths, which are significantly higher even in comparison with serious diseases such as HIV and tuberculosis.

Globally, the market is predicted to grow at a CAGR of 2.7% in the forecast period, providing numerous opportunities for market players to invest in research and development in the hepatitis therapeutics market. The growing occurrence of hepatitis and higher death rate are major factors driving the need for specialized treatments and medicines, thus propelling the growth of the hepatitis therapeutics market over the forecast period. Hepatitis majorly occurred due to the inflammation of liver tissue, which is caused because of high alcohol consumption, drug abuse, viral infection, autoimmune diseases, and toxins.

Hepatitis is commonly bifurcated based on the time duration. For instance, if initial symptoms of hepatitis last for less than six months then it is referred to as acute hepatitis, else condition is referred to as chronic hepatitis in which symptoms remain active for more than six to eight months. The viral hepatitis is further classified into A, B, C, D, and E types.  Hepatitis B Virus also referred to as HBV and capable of infecting the liver that leads to chronic and acute liver disorders. HBV is commonly spread via blood and other types of body fluids to the affected patient. The hepatitis D virus or HDV is dependent on the HBV to duplicate and multiply itself in the human body. Hepatitis D virus is also considered a type of ribonucleic acid virus. The occurrence of hepatitis D and E is rare in comparison with other types of hepatitis. Hepatitis A virus is transmitted by the consummation of contaminated water, vegetables, and person-to-person contact. As per the world health organization (WHO) as many as ninety percent of the child above the age of ten are disease-ridden majorly due to poor hygiene and lack of sanitation.

Patients suffering from HIV-related diseases, with hepatitis C virus-infected sexual partners, receivers of contaminated blood, patients with a history of alcohol and drug abuse, and unhygienic conditions are at high risk of hepatitis. Recent technological advancements in healthcare infrastructure and improved therapeutic products to treat hepatitis are some of the critical factors boosting the growth of the hepatitis therapeutics market during the forecast period. Earlier, hepatitis C was considered not treatable due to the unavailability of reliable medicines, yet, with the advent of products similar to sovaldi and harvoni, a rise in the treatment rate has been observed.

The market is divided into regional market segments such as North America, Europe, Asia-Pacific, Latin America, and Africa. North America has shown major growth in recent years owing to the rising in disposable income, and growing awareness in patients for highly advanced therapeutics for the treatment of hepatitis in the region. Additionally, the adoption of the latest methodologies for the treatment of hepatitis, the prevalence of well-established healthcare infrastructure, and reimbursement are some of the critical factors attributing to the growth of the hepatitis therapeutics market in the region.

Asia-Pacific region is predicted to hold a major market share in the hepatitis therapeutics market with massive growth in the forecast period. Countries such as India, China, and Singapore are leading the Asia-Pacific market with increasing occurrence of hepatitis diseases, easy access to medicines and treatment in developing economies, a major emphasis on healthcare and sanitation by regional governments, and increasing awareness about hepatitis vaccination. The key players in the hepatitis therapeutics market are Gilead Co., Johnson & Johnson Inc., Bristol-Myers Squibb Company, Merck & Corporations, and AbbVie Incorporations.

Market Segment:

Disease Type Outlook (Revenue, USD Million, 2014 - 2025)
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Others

Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • UK
    • the Asia Pacific
        • China
        • Japan
    • Latin America
        • Brazil
        • Mexico
    • Middle East & Africa
        • South Africa